Previous 10 | Next 10 |
HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin ( TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that...
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON PR Newswire WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc ., a clinical-stage pharmaceutical company focused on developing transformative ther...
2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...
2023-05-24 09:24:44 ET vTv Therapeutics ( NASDAQ: VTVT ) added ~13% in the pre-market Wednesday after announcing that its partner Cantex Pharmaceuticals received a U.S. patent that covers claims related to experimental brain tumor therapy azeliragon. In June 2021, Cantex rea...
HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that the United States Patent and Tradem...
2023-05-11 17:15:05 ET vTv Therapeutics press release ( NASDAQ: VTVT ): Q1 GAAP EPS of -$0.06 beats by $0.05 . The Company’s cash position as of March 31, 2023, was $18.8 million compared to $12.1 million as of December 31, 2022. The increase is attrib...
HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter e...
2023-05-07 12:00:27 ET Patients in the U.S are expected to dish out $10B on obesity medicines in 2027, marking an $8.1B rise or over 378% growth for the period 2023 – 2027, the latest industry report on pharma spending from the drug analytics firm IQVIA Holdings ( IQV ) indicates...
2023-04-27 06:55:09 ET Eli Lilly ( NYSE: LLY ) announced Thursday that its experimental weight loss therapy, tirzepatide, generated up to 15.7% of weight loss, and the company expects the FDA to decide on its approval as early as late 2023. Tirzepatide, a glucose-dependent insul...
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 PR Newswire WESTON, Fla. and ANN ARBOR, M...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...